These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19741266)

  • 1. Biomarkers in chronic obstructive pulmonary disease.
    Sin DD; Vestbo J
    Proc Am Thorac Soc; 2009 Sep; 6(6):543-5. PubMed ID: 19741266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers in chronic obstructive pulmonary disease.
    Rosenberg SR; Kalhan R
    Transl Res; 2012 Apr; 159(4):228-37. PubMed ID: 22424427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary biomarkers in chronic obstructive pulmonary disease.
    Barnes PJ; Chowdhury B; Kharitonov SA; Magnussen H; Page CP; Postma D; Saetta M
    Am J Respir Crit Care Med; 2006 Jul; 174(1):6-14. PubMed ID: 16556692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomics-based biomarkers in chronic obstructive pulmonary disease.
    Chen H; Wang D; Bai C; Wang X
    J Proteome Res; 2010 Jun; 9(6):2798-808. PubMed ID: 20387909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood specimen biomarkers of inflammation, matrix degradation, angiogenesis, and cardiac involvement: a future useful tool in assessing clinical outcomes of COPD patients in clinical practice?
    Kristan SS
    Arch Immunol Ther Exp (Warsz); 2013 Dec; 61(6):469-81. PubMed ID: 23703244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biomarkers in COPD--do we need them?].
    Batura-Gabryel H
    Pneumonol Alergol Pol; 2011; 79(2):144-50. PubMed ID: 21351067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases.
    Disse B
    Novartis Found Symp; 2002; 248():254-72; discussion 272-6, 277-82. PubMed ID: 12568499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of distinct plasma biomarker signatures in patients with rapid and slow declining forms of COPD.
    Devanarayan V; Scholand MB; Hoidal J; Leppert MF; Crackower MA; O'Neill GP; Gervais FG
    COPD; 2010 Feb; 7(1):51-8. PubMed ID: 20214463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of exhaled breath condensate pH as a biomarker for COPD.
    MacNee W; Rennard SI; Hunt JF; Edwards LD; Miller BE; Locantore NW; Tal-Singer R
    Respir Med; 2011 Jul; 105(7):1037-45. PubMed ID: 21377342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic obstructive pulmonary disease exacerbations in emergency departments: predictors of outcome.
    Roche N; Rabbat A; Zureik M; Huchon G
    Curr Opin Pulm Med; 2010 Mar; 16(2):112-7. PubMed ID: 20019614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease.
    Hurst JR; Donaldson GC; Perera WR; Wilkinson TM; Bilello JA; Hagan GW; Vessey RS; Wedzicha JA
    Am J Respir Crit Care Med; 2006 Oct; 174(8):867-74. PubMed ID: 16799074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers in obstructive respiratory diseases: an update.
    Braido F; Bagnasco D; Scichilone N; Santus P; Solidoro P; Di Marco F; Corsico A; Canonica GW
    Panminerva Med; 2012 Jun; 54(2):119-27. PubMed ID: 22525566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease.
    Ágh T; Inotai A; Mészáros Á
    Respiration; 2011; 82(4):328-34. PubMed ID: 21454953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function.
    Eickmeier O; Huebner M; Herrmann E; Zissler U; Rosewich M; Baer PC; Buhl R; Schmitt-Grohé S; Zielen S; Schubert R
    Cytokine; 2010 May; 50(2):152-7. PubMed ID: 20181491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations.
    Antonescu-Turcu AL; Tomic R
    Curr Opin Pulm Med; 2009 Mar; 15(2):120-5. PubMed ID: 19532026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix elastin: a promising biomarker for chronic obstructive pulmonary disease.
    Turino GM; Ma S; Lin YY; Cantor JO; Luisetti M
    Am J Respir Crit Care Med; 2011 Sep; 184(6):637-41. PubMed ID: 21757624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid metabolite levels of prostaglandin D2 and eicosapentaenoic acid recovered from bronchoalveolar lavage fluid correlate with lung function of chronic obstructive pulmonary disease patients and controls.
    Csanky E; Rühl R; Scholtz B; Vasko A; Takacs L; Hempel WM
    Electrophoresis; 2009 Apr; 30(7):1228-34. PubMed ID: 19294692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surfactant protein D: a lung specific biomarker in COPD?
    Sin DD; Pahlavan PS; Man SF
    Ther Adv Respir Dis; 2008 Apr; 2(2):65-74. PubMed ID: 19124360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker discovery in asthma and COPD by proteomic approaches.
    Rossi R; De Palma A; Benazzi L; Riccio AM; Canonica GW; Mauri P
    Proteomics Clin Appl; 2014 Dec; 8(11-12):901-15. PubMed ID: 25186471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The influence of inflammatory process on the ventilatory impairment in patients with stable chronic obstructive pulmonary disease].
    Komnata K
    Pneumonol Alergol Pol; 2010; 78(4):271-8. PubMed ID: 20665447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.